These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25243894

  • 21. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2012 Nov 05; 9(11):3236-45. PubMed ID: 23020847
    [Abstract] [Full Text] [Related]

  • 22. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2011 Dec 05; 339(3):935-44. PubMed ID: 21934030
    [Abstract] [Full Text] [Related]

  • 23. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O.
    Invest New Drugs; 2012 Apr 05; 30(2):443-9. PubMed ID: 20963470
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.
    Nucl Med Biol; 2013 Oct 05; 40(7):873-8. PubMed ID: 23845421
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
    Fuchs H, Kishimoto W, Gansser D, Tanswell P, Ishiguro N.
    Drug Metab Dispos; 2014 Oct 05; 42(10):1761-5. PubMed ID: 25053619
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T, Agarwal S, Elmquist WF.
    J Pharmacol Exp Ther; 2012 May 05; 341(2):386-95. PubMed ID: 22323823
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
    Oberoi RK, Mittapalli RK, Elmquist WF.
    J Pharmacol Exp Ther; 2013 Dec 05; 347(3):755-64. PubMed ID: 24113148
    [Abstract] [Full Text] [Related]

  • 31. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
    Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF.
    Drug Metab Dispos; 2014 Aug 05; 42(8):1292-300. PubMed ID: 24875464
    [Abstract] [Full Text] [Related]

  • 32. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 33. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.
    J Pharmacol Exp Ther; 2012 Jul 15; 342(1):33-40. PubMed ID: 22454535
    [Abstract] [Full Text] [Related]

  • 34. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 15; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 35. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
    Bauer F, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Mairinger S, Dörner B, Löscher W, Müller M, Erker T, Langer O.
    Bioorg Med Chem; 2010 Aug 01; 18(15):5489-97. PubMed ID: 20621487
    [Abstract] [Full Text] [Related]

  • 36. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
    Bankstahl JP, Bankstahl M, Römermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Müller M, Löscher W, Langer O, Kuntner C.
    Drug Metab Dispos; 2013 Apr 01; 41(4):754-62. PubMed ID: 23305710
    [Abstract] [Full Text] [Related]

  • 37. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 38. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
    Nakanishi H, Yonezawa A, Matsubara K, Yano I.
    Eur J Pharmacol; 2013 Jun 15; 710(1-3):20-8. PubMed ID: 23588114
    [Abstract] [Full Text] [Related]

  • 39. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice.
    Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC.
    Stem Cells; 2005 Sep 15; 23(8):1059-65. PubMed ID: 16002779
    [Abstract] [Full Text] [Related]

  • 40. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
    Savolainen H, Cantore M, Colabufo NA, Elsinga PH, Windhorst AD, Luurtsema G.
    Mol Pharm; 2015 Jul 06; 12(7):2265-75. PubMed ID: 26043236
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.